| Similar Articles |
|---|
 |
The Motley Fool
April 2, 2007
Brian Lawler |
Pain Therapeutics Pares Shares The small drugmaker announces a share buyback.   |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
September 18, 2007
Brian Lawler |
Direct Your Attention to DURECT Promising drug test results make DURECT a company to watch. The tiny drugmaker has a host of important milestones coming up over the next year. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
December 11, 2008
Brian Orelli |
A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone. |
The Motley Fool
November 2, 2007
Brian Lawler |
A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note. |
The Motley Fool
March 1, 2007
Brian Lawler |
King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter. |
The Motley Fool
January 6, 2012
David Williamson |
Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
The Motley Fool
June 24, 2011
Brian Orelli |
Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why? |
The Motley Fool
February 28, 2008
Brian Lawler |
Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful. |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years. |
The Motley Fool
July 6, 2007
Brian Orelli |
Pain-Free Phase 2 Data Anesiva's pain medication is moving up the clinical trial ladder. The Adlea results are very promising, but investors should look at the state of the entire company before investing. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
June 27, 2011
Brian Orelli |
Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections. |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals. |
The Motley Fool
October 8, 2007
Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics... |
The Motley Fool
July 18, 2007
Brian Orelli |
Pain-Free Payday for DURECT Results from a trial take it one step closer to possible approval for a local anesthetic. Because the platform can be used with different types of drugs, DURECT could try to win additional partnerships. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
May 28, 2008
Brian Lawler |
King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another. |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
The Motley Fool
March 30, 2005
David Nierengarten |
Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives? |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
November 30, 2006
Brian Lawler |
Durect's Pain-Free Deal A partnership deal has investors in the small specialty pharma excited. |
The Motley Fool
November 5, 2007
Brian Lawler |
King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
August 29, 2011
Brian Orelli |
A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER. |
BusinessWeek
June 14, 2004
Gene G. Marcial |
From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
July 24, 2007
Brian Lawler |
Pain and Alpharma Gain From Purdue's Slip Purdue Frederick Company pays a high price for misleading the public about its pain drug OxyContin; other drugmakers stand to benefit from it. |
The Motley Fool
December 9, 2008
Brian Orelli |
Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
June 20, 2011
Brian Orelli |
Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next. |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
June 22, 2011
Brian Orelli |
Building on Pfizer's Blockbuster New data for an expanded indication for Lyrica. |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
August 22, 2007
Brian Orelli |
Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
Managed Care
October 2003
Martin Sipkoff |
Pain Management: Health Plans Need to Take Control Insurers have not focused much on chronic pain. They should. It presents a humanitarian and business opportunity. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
Chemistry World
January 12, 2015
Phillip Broadwith |
Biogen Idec to buy Convergence for pain pipeline The deal gives Biogen Idec access to a promising candidate for neuropathic pain, but also significant R&D expertise in pain and neurology. |
BusinessWeek
January 17, 2005
Catherine Arnst |
No Pain, Some Gain The 50 million Americans suffering from chronic pain got a little bit of good news in December. The Food & Drug Administration greenlighted two new medications that attack pain in completely novel ways. |
American Journal of Nursing
March 2011
Jablonski et al. |
The Use of Algorithms in Assessing and Managing Persistent Pain in Older Adults This article introduces readers to the use of algorithms in guiding the assessment and management of persistent pain in older adults, and provides an illustrative case study. |
Salon.com
October 2, 2000
Lynn O'Dell |
Pain in the brain The good news? The hurt is all in your mind. The bad news? The hurt is all in your mind... |
